Glaucoma Clinical Trial

Currently, the only treatment for glaucoma is to lower the eye pressure to reduce the stress on the optic nerve and hopefully slow down the rate of glaucoma damage. But what if we could directly stop the damage through medical therapy?

Eye Associates is partnering with ONL Therapeutics in a clinical trial of a new drug called ONL1204. ONL 1204 directly blocks the receptor whose activation starts the process of nerve cell death. The trial hopes to answer the question whether doing this is a safe and tolerable way to treat glaucoma.

For this trial we are looking for patients with moderately bad glaucoma, whose disease is getting worse even though their pressure is not particularly high. Like most clinical trials, there are quite a few specific inclusion and exclusion criteria. If you think you might be interested in participating in the ONL 1204 trial, please speak to your Eye Associates doctor about it, or contact us at trials@eyeassociates.com.au